Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19.1 Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free.2 However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.3- 5 To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: September 13, 2022.
Published: November 9, 2022. doi:10.1001/jamanetworkopen.2022.41144
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Khazanchi R et al. JAMA Network Open.
Corresponding Author: Rohan Khazanchi, MD, MPH, Brigham & Women’s Hospital, 75 Francis St, Boston, MA 02115 (firstname.lastname@example.org).
Author Contributions: Dr Khazanchi and Mr Strumpf had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Khazanchi, Strumpf, Powers, McManus.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Khazanchi, Essien.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Khazanchi, Strumpf, Powers.
Obtained funding: McManus.
Administrative, technical, or material support: Strumpf, Powers, McManus.
Conflict of Interest Disclosures: Dr Khazanchi reported receiving personal fees from the New York City Department of Health and Mental Hygiene and grants from the Infectious Diseases Society of America Foundation outside the submitted work. Dr Essien reported receiving grants from the Department of Veterans Affairs outside the submitted work. Mr Powers reported receiving grants from the University of Virginia Global Infectious Diseases Institute during the conduct of the study. Dr McManus reported receiving grants from and owning stock in Gilead Sciences Inc outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by the University of Virginia Global Infectious Diseases Institute.
Role of the Funder/Sponsor: The University of Virginia Global Infectious Diseases Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: The statistical code is available on request from Mr Strumpf (email@example.com). Data sets are publicly available from sources noted in Methods.
You currently have no searches saved.
You currently have no courses saved.